Lactate MRSI and DCE MRI as surrogate markers of prostate tumor aggressiveness

NMR in Biomedicine

Volumn 25, Issue 1, 2012, Pages 113-122

  Yaligar, J ^a   Thakur, S B ^a   Bokacheva, L ^a   Carlin, S ^a   Thaler, H T ^a   Rizwan, A ^a   Lupu, M E ^a   Wang, Y ^a   Matei, C C ^a   Zakian, K L ^a   Koutcher, J A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

DCE MRI; Dunning R3327 AT; Dunning R3327 H; Immunohistochemistry; Lactate; MRSI; Prostate; Sel MQC

Indexed keywords

DCE-MRI; DUNNING R3327-AT; DUNNING R3327-H; IMMUNOHISTOCHEMISTRY; LACTATE; MRSI; PROSTATE; SEL-MQC;

ACETIC ACID; GADOLINIUM; QUANTUM THEORY;

TUMORS;

GADOLINIUM; LACTIC ACID; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SIZE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; HISTOPATHOLOGY; HYPOXIA; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERMEABILITY; PRIORITY JOURNAL; PROSTATE CANCER; RAT; TISSUE PERFUSION; TUMOR VOLUME;

ANIMALS; CELL HYPOXIA; CONTRAST MEDIA; IMMUNOHISTOCHEMISTRY; LACTIC ACID; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; NECROSIS; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; RATS; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

RATTUS;

EID: 84855903848     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1723     Document Type: Article

References (51)

1. Miller DC, Gruber SB, Hollenbeck BK, Montie JE, Wei JT. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J. Natl. Cancer Inst. 2006; 98: 1134-1141.
2. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J. Clin. Oncol. 2004; 22: 2141-2149.
3. Chun FK, Karakiewicz PI, Huland H, Graefen M. Role of nomograms for prostate cancer in 2007. World J. Urol. 2007; 25: 131-142.
4. Steyerberg EW, Roobol MJ, Kattan MW, van der Kwast TH, de Koning HJ, Schroder FH. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J. Urol. 2007; 177: 107-112.
5. Nowell PC. The clonal evolution of tumor cell populations. Science, 1976; 194: 23-28.
6. Gao C, Furge K, Koeman J, Dykema K, Su Y, Cutler ML, Werts A, Haak P, Vande Woude GF. Chromosome instability, chromosome transcriptome, and clonal evolution of tumor cell populations. Proc. Natl. Acad. Sci. USA, 2007; 104: 8995-9000.
7. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, El-Naggar AK, Lozano G. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell, 2004; 119: 861-872.
8. Perryman LA, Blair JM, Kingsley EA, Szymanska B, Ow KT, Wen VW, MacKenzie KL, Vermeulen PB, Jackson P, Russell PJ. Over-expression of p53 mutants in LNCaP cells alters tumor growth and angiogenesis in vivo. Biochem. Biophys. Res. Commun. 2006; 345: 1207-1214.
9. Okawa T, Michaylira CZ, Kalabis J, Stairs DB, Nakagawa H, Andl CD, Johnstone CN, Klein-Szanto AJ, El-Deiry WS, Cukierman E, Herlyn M, Rustgi AK. The functional interplay between EGFR overexpression, hTERT activation, and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion, and differentiation. Genes Dev. 2007; 21: 2788-2803.
10. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 1993; 74: 957-967.
11. Li G, Bush JA, Ho VC. p53-dependent apoptosis in melanoma cells after treatment with camptothecin. J. Invest. Dermatol. 2000; 114: 514-519.
12. Walenta S, Wetterling M, Lehrke M, Schwickert G, Sundfor K, Rofstad EK, Mueller-Klieser W. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res. 2000; 60: 916-921.
13. Walenta S, Salameh A, Lyng H, Evensen JF, Mitze M, Rofstad EK, Mueller-Klieser W. Correlation of high lactate levels in head and neck tumors with incidence of metastasis. Am. J. Pathol. 1997; 150: 409-415.
14. Bhujwalla ZM, Glickson JD. Detection of tumor response to radiation therapy by in vivo proton MR spectroscopy. Int. J. Radiat. Oncol. Biol. Phys. 1996; 36: 635-639.
15. 1H nuclear magnetic resonance spectroscopy: effect of 5-fluorouracil on lactate levels in radiation-induced fibrosarcoma 1 tumors. Cancer Res. 1998; 58: 1063-1067.
16. Terpstra M, High WB, Luo Y, de Graaf RA, Merkle H, Garwood M. Relationships among lactate concentration, blood flow and histopathologic profiles in rat C6 glioma. NMR Biomed. 1996; 9: 185-194.
17. Tennant TR, Kim H, Sokoloff M, Rinker-Schaeffer CW. The Dunning model. Prostate, 2000; 43: 295-302.
18. Yeh KA, Biade S, Lanciano RM, Brown DQ, Fenning MC, Babb JS, Hanks GE, Chapman DC. Polarographic needle electrode measurements of oxygen in rat prostate carcinomas: accuracy and reproducibility. Int. J. Radiat. Oncol. Biol. Phys. 1995; 33: 111-118.
19. Zhao D, Constantinescu A, Chang CH, Hahn EW, Mason RP. Correlation of tumor oxygen dynamics with radiation response of the Dunning prostate R3327-HI tumor. Radiat. Res. 2003; 159: 621-631.
20. Zhao D, Ran S, Constantinescu A, Hahn EW, Mason RP. Tumor oxygen dynamics: correlation of in vivo MRI with histological findings. Neoplasia, 2003; 5: 308-318.
21. Thorndyke C, Meeker BE, Thomas G, Lakey WH, McPhee MS, Chapman JD. The radiation sensitivities of R3327-H and R3327-AT rat prostate adenocarcinomas. J. Urol. 1985; 134: 191-198.
22. Daehlin L, Damber JE. Blood flow in the Dunning R3327H rat prostatic adenocarcinoma; effects of oestradiol and testosterone. Urol. Res. 1986; 14: 113-117.
23. Pugachev A, Ruan S, Carlin S, Larson SM, Campa J, Ling CC, Humm JL. Dependence of FDG uptake on tumor microenvironment. Int. J. Radiat. Oncol. Biol. Phys. 2005; 62: 545-553.
24. He Q, Shungu DC, van Zijl PC, Bhujwalla ZM, Glickson JD. Single-scan in vivo lactate editing with complete lipid and water suppression by selective multiple-quantum-coherence transfer (Sel-MQC) with application to tumors. J. Magn. Reson. B, 1995; 106: 203-211.
25. Thakur SB, Yaligar J, Koutcher JA. In vivo lactate signal enhancement using binomial spectral-selective pulses in selective MQ coherence (SS-SelMQC) spectroscopy. Magn. Reson. Med. 2009; 62: 591-598.
26. Muruganandham M, Koutcher JA, Pizzorno G, He Q. In vivo tumorlactate relaxation measurements by selective multiple-quantum-coherence (Sel-MQC) transfer. Magn. Reson. Med. 2004; 52: 902-906.
27. Danielsen ER, Michaelis T, Ross BD. Three methods of calibration in quantitative proton MR spectroscopy. J. Magn. Reson. B, 1995; 106: 287-291.
28. Naressi A, Couturier C, Castang I, de Beer R, Graveron-Demilly D. Java-based graphical user interface for MRUI, a software package for quantitation of in vivo/medical magnetic resonance spectroscopy signals. Comput. Biol. Med. 2001; 31: 269-286.
29. Hoffmann U, Brix G, Knopp MV, Hess T, Lorenz WJ. Pharmacokinetic mapping of the breast: a new method for dynamic MR mammography. Magn. Reson. Med. 1995; 33: 506-514.
30. Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J. Magn. Reson. Imaging, 1997; 7: 91-101.
31. Brix G, Semmler W, Port R, Schad LR, Layer G, Lorenz WJ. Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J. Comput. Assist. Tomogr. 1991; 15: 621-628.
32. Cho H, Ackerstaff E, Carlin S, Lupu ME, Wang Y, Rizwan A, O'Donoghue J, Ling CC, Humm JL, Zanzonico PB, Koutcher JA. Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor model of tumor hypoxia. Neoplasia, 2009; 11: 247-259.
33. Brizel DM, Schroeder T, Scher RL, Walenta S, Clough RW, Dewhirst MW, Mueller-Klieser W. Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 2001; 51: 349-353.
34. Walenta S, Chau TV, Schroeder T, Lehr HA, Kunz-Schughart LA, Fuerst A, Mueller-Klieser W. Metabolic classification of human rectal adenocarcinomas: a novel guideline for clinical oncologists? J. Cancer Res. Clin. Oncol. 2003; 129: 321-326.
35. 31P magnetic resonance spectroscopy. J. Urol. 1993; 150: 2019-2024.
36. 1H HR-MAS spectroscopy. Magn. Reson. Med. 2006; 55: 1257-1264.
37. 1H HR-MAS spectroscopy of biopsy tissues. Magn. Reson. Med. 2008; 60: 510-516.
38. Chen AP, Albers MJ, Cunningham CH, Kohler SJ, Yen YF, Hurd RE, Tropp J, Bok R, Pauly JM, Nelson SJ, Kurhanewicz J, Vigneron DB. Hyperpolarized C-13 spectroscopic imaging of the TRAMP mouse at 3T - initial experience. Magn. Reson. Med. 2007; 58: 1099-1106.
39. 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Res. 2008; 68: 8607-8615.
40. Schally AV, Redding TW, Comaru-Schally AM. Inhibition of prostate tumors by agonistic and antagonistic analogs of LH-RH. Prostate, 1983; 4: 545-552.
41. Isaacs JT, Coffey DS. Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res. 1981; 41: 5070-5075.
42. Redding TW, Schally AV. Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone. Proc. Natl. Acad. Sci. USA, 1981; 78: 6509-6512.
43. George DJ, Dionne CA, Jani J, Angeles T, Murakata C, Lamb J, Isaacs JT. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer Res. 1999; 59: 2395-2401.
44. Mador D, Ritchie B, Meeker B, Moore R, Elliott FG, McPhee MS, Chapman JD, Lakey WH. Response of the Dunning R3327H prostatic adenocarcinoma to radiation and various chemotherapeutic drugs. Cancer Treat. Rep. 1982; 66: 1837-1843.
45. Sanda MG, Ayyagari SR, Jaffee EM, Epstein JI, Clift SL, Cohen LK, Dranoff G, Pardoll DM, Mulligan RC, Simons JW. Demonstration of a rational strategy for human prostate cancer gene therapy. J. Urol. 1994; 151: 622-628.
46. Loening SA, Bonney WW, Fallon B, Gerber WL, Hawtrey CE, Lubaroff DM, Narayana AS, Culp DA. Cryotherapy. Prostate, 1984; 5: 199-204.
47. Tiwari RK, Geliebter J, Garikapaty VP, Yedavelli SP, Chen S, Mittelman A. Anti-tumor effects of PC-SPES, an herbal formulation in prostate cancer. Int. J. Oncol. 1999; 14: 713-719.
48. Hall M, Silverman L, Wenger AS, Mickey DD. Oncodevelopmental enzymes of the Dunning rat prostatic adenocarcinoma. Cancer Res. 1985; 45: 4053-4059.
49. Lubaroff DM, Culp DA. Experience with an animal model for the study of prostatic carcinoma. Trans. Am. Assoc. Genitourin. Surg. 1977; 69: 72-77.
50. Wang W, Epstein JI. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am. J. Surg. Pathol. 2008; 32: 65-71.
51. Cai G, Ramdall RB, Levine P, Yang GC. Fine-needle aspiration of metastatic prostatic neuroendocrine carcinomas: cytomorphologic and immunophenotypic features. Diagn. Cytopathol. 2008; 36: 545-549.